ImmunityBio

United States
Los Angeles, California, United States, 90232

Company profile

ImmunityBio company profile

NantCel is an offshoot of Soon-Shiong's NantWorks conglomerate, developing molecular-level cell-based treatments for diseases. The company discovers and develop immunology based treatments for diseases through cell-based treatments at the molecular level. NantCell was formerly known as NantBioCell. It operates as a subsidiary of NantWorks.

Business identity

Contact email
[email protected]
Phone number
+1 844-696-5235
Operating status
Active
Company type
For Profit
Employee range
501-1,000 employees
Revenue range
$1M-$10M
Founded
2014-01-01, Year

Headquarters

Postal code
90232
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
16
Total equity funding
$914.7M
Last funding
Post IPO Equity / $80M / 2025-07-25
Last equity funding
Post IPO Equity / $80M
Investors
3
Lead investors
3
Founders
1
Articles
352
Exited on
2021-03-10

Founders and investors

Founders

Patrick Soon-Shiong

Lead investors

NantCapitalOberland CapitalPatrick Soon-Shiong

Investors

NantCapitalOberland CapitalPatrick Soon-Shiong